Related by context. All words. (Click for frequent words.) 72 leukemia CML 67 cytogenetic responses 66 cytogenetic response 66 complete cytogenetic 66 Gleevec resistant 65 Ph + acute lymphoblastic 65 metastatic malignant 64 Leukemias 64 CLL SLL 64 chronic myelogenous leukemia CML 63 haematologic 63 complete cytogenetic response 63 chronic myeloid leukemia CML 63 Diffuse Large B 62 mutated K ras 62 del 5q 62 CR CRu 62 leukemia ALL 62 azacytidine 62 CCyR 62 monocytic 62 Chronic lymphocytic leukemia CLL 62 MCyR 62 leukemia AML 62 Nilotinib 62 colorectal carcinoma 61 Glioblastoma Multiforme 61 NMIBC 61 bronchoalveolar lavage 61 lymphocytic leukemia 61 acute myeloid 61 relapsed refractory 61 ara C 61 CD# CD# 61 HER2 overexpression 61 imatinib therapy 61 Acute Myeloid Leukaemia AML 60 lymphocytosis 60 SSc 60 chronic myeloid 60 pediatric acute lymphoblastic 60 Decitabine 60 partial remissions 60 CVP chemotherapy 60 biochemical relapse 60 Non Hodgkin 60 PEG IFN 60 virological response 60 essential thrombocythemia 60 Ph + CML 60 FluCAM arm 60 fluconazole resistant 60 Myelodysplastic Syndrome MDS 60 IFN α 60 Tyrosine Kinase Inhibitor 60 CHOP chemotherapy 60 histologic subtype 60 dasatinib Sprycel 60 MALT lymphoma 60 Solid Tumors criteria 60 nucleotide analog 60 LPS induced 60 TNFalpha 60 demyelinating 60 chlorambucil 60 imatinib resistant 60 Fludarabine 59 peripheral blood mononuclear 59 acute GvHD 59 hypereosinophilic syndrome 59 Relapsed Refractory 59 invasive ductal 59 Omacetaxine 59 imatinib Gleevec 59 lymphopenia 59 NQO1 59 tumor regressions 59 alanine aminotransferase ALT 59 Partial Response 59 non Hodgkin lymphomas 59 imatinib resistance 59 Squamous 59 K ras mutations 59 Bosutinib 59 breast carcinomas 59 multiple myeloma MM 59 IL 1ß 59 Stomatitis 59 log# reduction 59 JAK2 V#F 59 refractory CML 59 EGFR TKI 59 nadolol 59 HBeAg 59 gefitinib Iressa 59 hematologic toxicity 59 Epratuzumab 59 Gleevec imatinib mesylate 59 MLH1 59 Chronic Myelogenous Leukemia 59 Pathway Inhibitor 59 lymphoid malignancies 59 myeloproliferative 59 refractory cutaneous T 59 thrombocytosis 59 PEGylated Fab fragment 59 Chronic Myeloid Leukemia 59 Leydig cell 59 HLA DR4 59 T1c 59 PAOD 59 refractory chronic lymphocytic 59 Antigen Specific 59 rheumatoid factor 59 cis retinoic acid 59 remission CR 58 Interferon gamma 58 hepatocellular carcinomas 58 chronic eosinophilic leukemia 58 cytopenias 58 CIMZIA TM 58 B Cell Lymphoma 58 histological subtype 58 Mutational 58 pDC 58 thalidomide Thalomid 58 myeloproliferative diseases 58 Follicular 58 mitoxantrone chemotherapy 58 pT3 58 Pharmacokinetics PK 58 nutlin 3a 58 papillary renal cell carcinoma 58 mediated apoptosis 58 murine model 58 PegIFN RBV 58 Cutaneous T 58 HNSCC 58 astrocytomas 58 follicular Non Hodgkin 58 CRp 58 Lymphocytic 58 T#I [002] 58 paragangliomas 58 refractory chronic myeloid 58 dasatinib Sprycel ® 58 Clusterin 58 previously untreated follicular 58 Cell Lymphoma 58 Vidaza azacitidine 58 inducible nitric oxide synthase 58 certolizumab 58 tumor xenograft models 58 gastrointestinal stromal tumors GISTs 58 Ozarelix 58 Hodgkin lymphoma HL 58 leukemia CLL 58 leukaemias 58 Follicular Lymphoma 58 vWF 58 Fingolimod 58 eosinophilic asthma 58 lymphoid blast 58 relapsed MM 58 CR nPR 58 PTLD 58 Hypotension 58 achieved sustained virological 58 RECIST Response Evaluation Criteria 58 DLBCL 58 gemcitabine Gemzar 58 gastrointestinal stromal tumor 58 myeloproliferative disorder 58 osteosarcomas 58 haematological 58 seropositive patients 57 operable breast cancer 57 alkylating agent 57 colony stimulating factor 57 underwent resection 57 lymphocyte count 57 Philadelphia Chromosome Positive 57 enterococcal 57 CIN2 + 57 HER2 overexpressing 57 tumors GIST 57 adriamycin 57 KRAS mutations occur 57 polyposis 57 familial ALS 57 evaluable subjects 57 oblimersen 57 alfa 2a 57 epithelial tumors 57 Toxicities 57 renal cell carcinomas 57 Chronic Lymphocytic Leukemia 57 neoplasias 57 small lymphocytic lymphoma 57 FOLFOX6 57 sarcomatoid 57 hypophosphatemia 57 TMC# r 57 idiopathic thrombocytopenic purpura ITP 57 TTR gene 57 cell lymphoma CTCL 57 injected subcutaneously 57 Subtype 57 Fludara ® 57 biliary tract cancer 57 BRAF V#E 57 galiximab 57 liver histology 57 myeloperoxidase 57 Dasatinib 57 recurrent glioblastoma multiforme 57 anaplastic astrocytoma AA 57 annexin 57 Interferon Beta 57 Allogeneic 57 Chronic lymphocytic leukemia 57 lung carcinomas 57 replicon 57 cell adhesion molecule 57 AML acute myeloid 57 Malignant Melanoma 57 recovery CRp 57 endometrioid 57 antithymocyte globulin 57 Ph + ALL 57 AGHD 57 cisplatin resistant 57 demonstrated antitumor activity 57 tumoral 57 hypomethylation 57 Chronic Myelogenous Leukemia CML 57 seminomas 57 antigen CD# 57 Diabetic Neuropathy 57 myelofibrosis polycythemia vera 57 Neutrophil 57 ErbB2 positive 57 Myelofibrosis 57 eosinophilia 57 Dacogen decitabine 57 ductal adenocarcinoma 57 Irinotecan 57 deletion 5q 57 airway hyperresponsiveness 57 taxane chemotherapy 57 Antiviral Therapy 57 Soft Tissue Sarcoma 57 Retreatment 57 ritonavir boosted 57 neutropaenia 57 huN# DM1 57 diabetes mellitus DM 57 Acute myeloid leukemia 57 cisplatin chemotherapy 57 basal cell carcinoma BCC 57 metastatic lesions 57 Factor Receptor 57 papillary carcinoma 57 coagulase negative staphylococci 56 PDGFR 56 Akt activation 56 CIAS1 56 underwent surgical resection 56 caspofungin 56 histologically confirmed 56 Peginterferon 56 gastric adenocarcinoma 56 Fibroblast 56 acute lymphoblastic 56 adjunctive placebo 56 transcranial Doppler ultrasound 56 immunocompetent 56 thrombocytopenic patients 56 selective agonist 56 elevated ALT 56 PPAR gamma agonist 56 pCR 56 euthymic patients 56 clinically meaningful improvement 56 cyclophosphamide doxorubicin vincristine 56 PEGylated anti 56 MELAS 56 Flu Cy 56 colorectal adenocarcinoma 56 mg/m2/day 56 GW# [003] 56 HSCT 56 Catenin 56 MGd 56 GISTs 56 e antigen HBeAg 56 papillary thyroid carcinoma 56 cell acute lymphoblastic 56 Castration Resistant Prostate Cancer 56 thymoma 56 autoantibody positive 56 comparator arm 56 p# mitogen activated 56 depsipeptide 56 malignant ascites 56 Epstein Barr virus EBV 56 UGT#A# 56 chronic GVHD 56 alefacept 56 Inactivation 56 CIN3 56 dose melphalan 56 ERBB2 56 weekly intravenous infusions 56 trans retinoic acid 56 Macrophage 56 trastuzumab Herceptin ® 56 Pegylated Interferon 56 DOXIL ® 56 stage IIIb IV 56 Advanced Renal Cell 56 glioblastoma multiforme GBM 56 Enzastaurin 56 Bezielle 56 choriocarcinoma 56 Kit CD# positive 56 HCV SPRINT 56 receptor tyrosine kinase inhibitor 56 Oral Fingolimod 56 refractory NSCLC 56 cytoreduction 56 IgA deficiency 56 systemic anaplastic large 56 FLT3 56 hA# 56 precursor acute lymphoblastic 56 hepatorenal syndrome 56 Cytotoxic T 56 interferon ribavirin 56 unmutated 56 TPMT 56 myeloid 56 Multiple Myeloma MM 56 antibody MAb 56 neutropenia dehydration dyspnea 56 ovarian carcinoma 56 Pemetrexed 56 GBM tumors 56 dexamethasone Decadron 56 Degarelix 56 ALT flares 56 generalized tonic clonic seizures 56 gemcitabine Gemzar ® 56 constitutively activated 56 Glioma 56 splenectomized patients 56 Waldenstrom macroglobulinemia 56 metastatic malignant melanoma 56 gemcitabine carboplatin 56 MabCampath 56 lymphoproliferative disorder 56 radiotherapy RT 56 receptor blocker 56 haematological toxicity 56 demethylation 56 Janus kinase 56 locoregional recurrence 56 MAGE A3 ASCI 56 Ribavirin causes 56 chronic lymphocytic leukemia CLL 56 patients evaluable 56 KRAS wild 56 achieved CCyR 56 ß1 56 glioblastoma tumors 56 DOXIL 56 nilotinib 56 severe neutropenia 56 Bosentan 56 Prolongs Survival 56 syngeneic 56 systemic ALCL 56 cytogenetic abnormalities 56 Epidermal Growth Factor Receptor 56 fallopian tube cancers 56 prednisone prednisolone 56 HBeAg positive patients 56 Alemtuzumab 56 regulated kinase 56 gastrointestinal stromal tumors GIST 56 colorectal adenoma 56 ADPKD 56 breast carcinoma 56 Natalizumab 56 Complete Response CR 56 Kinoid 56 IgG4 56 decitabine 56 TNF antagonist 55 lung adenocarcinomas 55 Lymphoid 55 pegylated liposomal doxorubicin 55 cervical intraepithelial neoplasia 55 neutrophil counts 55 CVP cyclophosphamide vincristine 55 Response Evaluation Criteria 55 PhG alpha 1 55 Etanercept 55 idiopathic thrombocytopenic purpura 55 refractory AML 55 T#I mutation 55 Anthracycline 55 relapsed acute myelogenous 55 lymphocytic 55 INCB# [003] 55 RECIST criteria 55 intraepithelial neoplasia 55 Parathyroid Hormone 55 bacillus Calmette Guerin 55 Progenitor Cells 55 LHRH agonists 55 hyperalgesia 55 Myeloid 55 Myelodysplastic Syndromes 55 P selectin 55 pT2 55 CagA 55 PSADT 55 cyclophosphamide methotrexate 55 LHRH 55 ZACTIMA 55 Kepivance 55 mycophenolate mofetil MMF 55 Medullary thyroid cancer 55 node metastases 55 Camptosar ® 55 HBeAg positive 55 monocytes macrophages 55 mycosis fungoides 55 fluorouracil leucovorin 55 FOLFOX chemotherapy 55 iniparib BSI 55 immunomodulatory therapy 55 undetectable HBV DNA 55 Xanafide 55 monocyte chemotactic protein 55 CDAI 55 beta 1a 55 Chronic Lymphocytic Leukemia CLL 55 flavopiridol 55 dysplastic lesions 55 uricase 55 Astrocytoma 55 FOLPI 55 mutated KRAS 55 myelodysplastic myeloproliferative diseases 55 ribavirin RBV 55 Anaplastic 55 interstitial fibrosis 55 Lenalidomide 55 colon carcinoma 55 peginterferon alpha 2a 55 vWD 55 tipranavir ritonavir 55 glutamic acid decarboxylase 55 indolent NHL 55 bortezomib refractory 55 carcinoid 55 ANCA associated 55 squamous cell carcinoma SCC 55 gene rearrangements 55 T2DM 55 CDI recurrence 55 Imatinib 55 Mouse Model 55 Myelodysplastic Syndrome 55 Campath alemtuzumab 55 B lymphocyte 55 situ CIS 55 Acute myeloid leukemia AML 55 transgene expression 55 AAV2 55 daunorubicin 55 Parkinson Disease PD 55 Angioedema 55 hematologic 55 posttransplant 55 PTPN# 55 affective psychosis 55 HLA B# 55 Introgen ADVEXIN 55 gastrointestinal perforation 55 flutamide 55 DFMO 55 interleukin IL 55 paclitaxel cisplatin 55 abacavir Ziagen 55 haematologic malignancies 55 constitutively expressed 55 genotypic resistance 55 Rheumatoid Arthritis RA 55 Tubulin 55 imatinib Gleevec ® 55 TRAIL induced apoptosis 55 idiopathic PAH 55 bullous 55 topically administered 55 Hurthle cell 55 Lymphomas 55 chronic myeloid leukemia 55 detectable HCV RNA 55 NS#/#A protease 55 leukemia APL 55 Adenomas 55 immunological responses 55 riociguat 55 autoimmune hemolytic anemia 55 OvaRex MAb 55 response pCR 55 monogenic 55 atypical hemolytic uremic syndrome 55 BCR ABL 55 CIMZIA ™ 55 Placebo Controlled Study 55 Upregulation 55 Refractory Hodgkin Lymphoma 55 EGFR mutation positive 55 lenalidomide dexamethasone 55 micafungin 55 leukemic 55 Papillary 55 Doxil ® 55 pleomorphic 55 Telintra 55 PsA 55 myeloablative 55 corticosteroid therapy 55 beta interferons 55 leucopenia 55 VFEND 55 Ofatumumab 55 SGOT 55 5-fluorouracil/leucovorin 55 paraganglioma 55 Haptoglobin 55 steroid refractory ulcerative 55 clinically meaningful improvements 55 interleukin IL -# 55 FluCAM 55 ABCB1 55 cutaneous T 55 Cytochrome P# 55 mycophenolate mofetil 55 Zollinger Ellison syndrome 55 neurologic progression 55 Beta Amyloid 55 pheochromocytoma 55 CLL cells 55 Monoclonal antibody 55 complete remissions 54 low dose cytarabine 54 lymphoproliferative disorders 54 Wegener granulomatosis 54 IFN gamma 54 CMV infection 54 relapsed AML 54 lymphoma subtypes 54 Paraplatin ® 54 leukocyte adhesion 54 microsatellite instability 54 SPRYCEL ® 54 follicular lymphomas 54 T Cell Lymphoma 54 Prostatitis 54 NNRTI resistance 54 chronic granulomatous disease 54 PSMA ADC 54 Fluorouracil 54 erlotinib Tarceva ® 54 completely resected 54 neutropenia febrile neutropenia 54 pulmonary metastases 54 plus methotrexate 54 COL#A# 54 JMML 54 MSH2 54 interferon IFN 54 MYCN amplification 54 ‰ ¥ 54 dyskeratosis congenita 54 Chronic pancreatitis 54 novel VDA molecule 54 antiangiogenic therapy 54 weekly subcutaneous injections 54 8mg/kg 54 cancer mCRC 54 Randomized Study 54 bacterial prostatitis 54 Tyrosine Kinase Inhibitors 54 mepolizumab 54 achieved sustained virologic 54 baminercept 54 Chronic HCV 54 immune thrombocytopenic purpura ITP 54 mg kg dose 54 treatment naive genotype 54 HBeAg seroconversion 54 cidofovir 54 luteinizing hormone releasing 54 ZOLINZA 54 oral clodronate 54 CsA 54 plasma viremia 54 ribavirin therapy 54 visilizumab 54 sclerosing 54 pancreatic adenocarcinoma 54 hypoxia inducible factor 54 rapid virologic response 54 HCV RESPOND 2 54 MAGE A3 54 Escherichia coli Klebsiella pneumoniae 54 CYT# potent vascular disrupting 54 autosomal dominant disorder 54 radioiodine therapy 54 chemoradiotherapy 54 octreotide LAR 54 cardiotoxic 54 glycated hemoglobin levels 54 evaluable patients 54 efalizumab 54 tamoxifen Nolvadex ® 54 metastatic neuroendocrine tumors 54 hepatic cirrhosis 54 progressive neurodegenerative disorder 54 bleomycin 54 RezularTM 54 mediated immunity 54 immune thrombocytopenic purpura 54 Severe Primary IGFD 54 Vidaza ® 54 RhuDex R 54 Genotypes 54 Diabetic neuropathy 54 Amrubicin 54 chronic idiopathic 54 Hypertrophy 54 chronic idiopathic thrombocytopenic purpura 54 mitoxantrone plus 54 indolent lymphoma 54 combination antiretroviral therapy 54 subependymal giant cell 54 keloid scarring 54 post transplant lymphoproliferative 54 complement inhibitor eculizumab 54 carcinoid tumors 54 morphometric vertebral fractures 54 interferon beta therapy 54 lymphoblastic leukemia 54 nonsmall cell lung cancer 54 prostate adenocarcinoma 54 Pathogenesis 54 Sjögren syndrome 54 dacarbazine DTIC 54 molecular remissions 54 HCV infections 54 macroalbuminuria 54 hyperprolactinemia 54 graft dysfunction 54 intravascular hemolysis 54 serous ovarian cancer 54 acute humoral rejection 54 bladder carcinoma 54 SGPT 54 neoplastic 54 gastrointestinal stromal tumor GIST 54 endoscopic remission 54 TTF Therapy 54 tuberous sclerosis TS 54 polycythemia vera essential thrombocythemia 54 nonmetastatic 54 cytotoxin 54 Chronic Sinusitis 54 sustained virologic response 54 Thrombocytopenia 54 relapsed acute lymphoblastic 54 myoclonus 54 myeloid leukemia 54 MGUS 54 basiliximab 54 hyperphenylalaninemia HPA due 54 moderate renal impairment 54 sunitinib Sutent ® 54 Cyclophosphamide 54 antiandrogen 54 Bendamustine 54 mediated inhibition 54 rituximab refractory 54 bendamustine 54 pouchitis 54 Myelodysplastic syndromes MDS 54 EDSS scores 54 polyarticular 54 EXJADE 54 ibritumomab tiuxetan 54 Metastatic Colorectal Cancer 54 targeting CD# 54 hepatocellular cancer 54 AEG# 54 Platinol ® 54 HBeAg negative patients 54 Secretase 54 Relapsed 54 Overexpression 54 vesicular monoamine transporter 54 Thal Dex 54 extracellular signal 54 Targeted Therapy 54 PC# cells 54 Protease Inhibitor 54 invasive candidiasis 54 constipation predominant IBS 54 Orally administered 54 Cardiotoxicity 54 Copegus ribavirin 54 recurrent glioma 54 generation purine nucleoside 54 4mg/kg 54 Acute Lymphocytic Leukemia 54 Associated Adipose Redistribution 54 anthracycline containing 54 decarboxylase 54 hematopoietic progenitors 54 mCRC patients 54 lenalidomide Revlimid R 54 myeloproliferative neoplasms 54 AT1R 54 lysosomal storage disease 54 Monoclonal 54 CD# + [001] 54 Glioblastoma multiforme GBM 54 rituximab Rituxan 54 CD# mAb 54 Acute Myeloid Leukaemia 54 metastatic gastric 54 allograft rejection 54 Relapsed Refractory Aggressive 54 hematologic abnormalities 54 Pegasys ® 54 Carcinomas 54 estramustine 54 Combination therapy 54 metaplasia 54 advanced hepatocellular carcinoma 54 small molecule activator 54 missense mutation 54 moderately emetogenic 54 1beta 54 BN# [004] 54 neutropenic sepsis 54 seminoma 54 refractory Hodgkin 54 Copegus ® 54 endometrial adenocarcinoma 54 recurrent metastatic 54 HbF 54 CP CPPS 54 cisplatin gemcitabine 54 malignant lymphoma 54 alemtuzumab treated 54 grade cervical intraepithelial 54 leukoencephalopathy 53 methicillin susceptible Staphylococcus aureus 53 Acidosis 53 FOLFIRI alone 53 nodular partial response 53 Elagolix 53 pegylated interferon alfa 2a 53 Receptor Antagonists 53 ON #.Na 53 repolarization 53 brain lesions 53 immunocompetent patients 53 retinoic acid receptor 53 prostate cancer PCa 53 epithelioid 53 chronic myelogenous leukemia 53 plasma uric acid 53 prolonged QT interval 53 smoldering myeloma 53 autoantibody levels 53 cytopenia 53 erythematosus 53 ER CHOP 53 neutropenic patients 53 E#F# 53 genital herpes infections 53 recurrent genital herpes 53 cells PBMCs 53 Epstein Barr Virus 53 Systemic lupus erythematosus SLE 53 platelet reactivity 53 bronchial hyperresponsiveness 53 neuroendocrine cancers 53 transplantation HCT 53 chemoradiation therapy 53 refractory acute myeloid 53 nephrotoxic 53 Glycosylation 53 null mice 53 neurological manifestations 53 xenograft models 53 Tasimelteon 53 NAbs 53 receiving VICTRELIS 53 acute myelogenous leukemia AML 53 etanercept Enbrel 53 pilocytic astrocytoma 53 locoregional 53 dosing cohort 53 Helicobacter pylori eradication 53 BRCA1 BRCA2 53 Phase Ib Clinical Trial 53 placebo dexamethasone 53 Seliciclib 53 MS relapses 53 basal cell nevus syndrome 53 #mg QD [002] 53 CC genotype 53 relapsed leukemia 53 gastrointestinal stromal tumors 53 Relapsing Remitting Multiple Sclerosis 53 EGFRIs 53 external genital lesions 53 metastatic CRC 53 receptor monoclonal antibody 53 HGS ETR1 53 Metastases 53 NOMID 53 docetaxel chemotherapy 53 Gorlin syndrome 53 candidemia 53 DEB# 53 ribavirin Copegus ® 53 Lymphocyte 53 pancreatic neuroendocrine 53 TEAEs 53 TNF α 53 Chemokine Receptor 53 octreotide acetate 53 Hyperlipidemia 53 thrombocytopenic 53 albumin bound paclitaxel 53 treat benign prostatic 53 Tyrosine Kinase 53 MDS AML 53 HLA DRB1 * 53 CRu 53 PCNSL 53 PDGFRA 53 hepatitis C genotype 53 CCR5 tropic HIV 53 PRADAXA #mg 53 imatinib 53 androgen ablation 53 BARACLUDE ® 53 corticosteroid dose 53 Relapsing remitting MS 53 temozolomide TMZ 53 icatibant 53 Phase 2b Trial 53 hypoperfusion 53 Interferon alpha 53 associated lymphoid tissue 53 dual endothelin receptor antagonist 53 lung metastasis 53 heavily pretreated 53 Cimzia TM 53 cell lymphoma ALCL 53 gemcitabine cisplatin 53 mg m² 53 Follicular lymphoma 53 Azedra 53 Gliomas 53 PEGINTRON TM 53 cells μL 53 meropenem 53 benign prostatic hypertrophy BPH 53 systemic fungal infections 53 HER2 negative 53 Estrogen Receptor 53 EBV infection 53 WT1 53 serum calcium levels 53 etoposide 53 Synovial Sarcoma 53 transaminase elevations 53 metastatic GIST 53 interferon alfa 2b 53 Leber Hereditary Optic Neuropathy 53 herpesviruses 53 Rheumatoid 53 follicular NHL 53 relapsing multiple sclerosis 53 pan HDAC inhibitor 53 familial amyloidotic polyneuropathy FAP 53 CYP #D# 53 bortezomib Velcade 53 corticosteroid dexamethasone 53 Arrhythmogenic 53 5FU 53 activating mutation 53 Platinol ® cisplatin 53 timepoints 53 Chronic Prostatitis 53 upregulating 53 BCR ABL1 53 HDACi 53 tumor resection 53 elacytarabine 53 myelodysplastic syndrome MDS 53 symptomatic intracranial hemorrhage 53 Newly Diagnosed Multiple Myeloma 53 % CI #.#-#.# [007] 53 NPM1 53 anaplastic 53 bcl 2 53 allogeneic bone marrow 53 Cathepsin B 53 alpha1 53 achieved ACR# 53 cetuximab Erbitux ® 53 C1 INH deficiency 53 hepatitis C HCV 53 distant metastasis 53 posterior uveitis 53 steroid dexamethasone 53 Vidaza R 53 milatuzumab 53 cerebral vasospasm 53 Polymerase 53 PRTX 53 Tumor Necrosis Factor 53 QD dosing 53 human herpesvirus 53 hematopoietic cancers 53 urothelial carcinoma 53 imipramine Tofranil 53 telaprevir dosed 53 receiving highly emetogenic 53 tositumomab 53 Protease 53 refractory gout 53 p tau 53 Acute Myelogenous Leukemia AML 53 neointimal hyperplasia 53 parathyroidectomy 53 EpCAM 53 immunomodulatory agents 53 Exacerbation 53 cholangiocarcinoma 53 allelic variants 53 Complicated Skin 53 Pixantrone 53 Leucovorin 53 piperacillin tazobactam 53 lichen planus 53 metastatic renal cell carcinoma 53 metastatic colorectal carcinoma 53 Extracellular 53 fronto temporal dementia 53 FOLPI regimen 53 functional polymorphism 53 lymphoid cells 53 FOLFOX4 53 polycythemia vera PV 53 Cholangiocarcinoma 53 pyrazinamide 53 liposomal amphotericin B 53 dorsal root ganglion 53 mGluR 53 Sudhir Agrawal D.Phil 53 missense mutations 53 Alequel 53 doxorubicin cyclophosphamide 53 peritumoral brain edema 53 recurrent glioblastoma 53 blastic phase 53 recurrent GBM 53 recurrent venous thromboembolism 53 bronchogenic carcinoma 53 relapsing remitting 53 NPM1 mutations 53 Azacitidine 53 INGN 53 Neulasta ® 53 dasatinib 53 autosomal dominant polycystic kidney 53 Mantle Cell Lymphoma